Study registration: *
Publication Tang P, medRxiv, 2021
Dates: 2020-12-21 to 2021-07-21
Funding: Mixed (Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, the Ministry of Public Health and Hamad Medical Corporation, Qatar Genome Programme. )
Conflict of interest: no COI (First and last authors and trial statisticians declare no competing interests. Dr. Butt has received institutional grant funding from Gilead Sciences unrelated to the work presented in this paper. )

Methods

Study design:Test-negative
Description of participants: Resident population in multiple centres in Qatar
Inclusion criteria:
  • Resident population in Qatar
  • RT-PCR tested between March 23-July 21, 2021
  • vaccination by BNT162b2 or mRNA-1273
  • information available for the matching.

Exclusion criteria:
  • received mixed vaccines
  • received a vaccine other than BNT162b2 or mRNA-1273 (e.g., ChAdOx1)

Follow-up duration (months): 7.00
Vaccines:
  • 1 or 2 doses of BNT162b2, 21 days apart
  • 1 or 2 doses of mRNA-1273, 28 days apart
  • 1 or 2 doses of BNT162b2 or mRNA-1273
Variant description :
Variant name: Delta
Evidence: Direct evidence (effectiveness determined by sequencing cases)
Documents
available

Protocol

NR

Statistical plan

NR

Data-sharing stated: Yes
Data accessibility: a direct application for data access to Her Excellency the Minister of Public Health: https://www.moph.gov.qa/english/Pages/default.aspx
General comment Concerns mainly over uncontrolled confounding; in addition there are uncertainties over the possibility of selection bias in a test-negative design.